Centre for Urology Research, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia.
Centre for Urology Research, Faculty of Health Sciences and Medicine, Bond University, Robina, Queensland, Australia
J Pharmacol Exp Ther. 2018 Aug;366(2):282-290. doi: 10.1124/jpet.118.248989. Epub 2018 May 21.
Inflammation may play a causal role in urological side effects reported following intravesical mitomycin C (MMC). Our aim was to investigate the effects of the nonsteroidal anti-inflammatory drug ibuprofen (IBU) on the cytotoxic potency of MMC and the potential for IBU to protect against bladder dysfunction. Malignant (RT4, T24) and normal (UROtsa) urothelial lines were treated with MMC followed by ibuprofen, with cell viability and caspase-3 activity assessed. Female C57BL/6JArc mice (Saline/Control, MMC, Saline + IBU, and MMC + IBU) received intravesical treatment (1 hour) with saline or MMC (2 mg/ml), with IBU (1 mg/ml) delivered in drinking water (for 7 days). Voiding pattern analysis was conducted prior to and following (1, 3, 7 days) treatment. A whole-bladder preparation was used to assess compliance, contractile responses, and urothelial-mediator release. Ibuprofen selectively increased the cytotoxic potency of MMC and caspase-3 activity in both malignant cells lines but not in UROtsa. MMC significantly increased voiding frequency at 24 hours and 3 days, whereas administration of ibuprofen significantly reduced this effect. MMC significantly increased the frequency of spontaneous contractions from 2.3 ± 0.5 contractions/min in saline controls to 4.8 ± 0.16 contractions/min, with ibuprofen protecting against this change. Interestingly, although nerve-evoked responses were not altered by MMC, they were increased in both IBU groups. Ibuprofen improved voiding dysfunction following MMC treatment by reducing spontaneous phasic activity and enhancing nerve-mediated contractions. Ibuprofen use in bladder cancer patients may help to minimize the urological adverse effects associated with intravesical MMC.
炎症可能在膀胱内丝裂霉素 C (MMC) 治疗后引起的泌尿科副作用中起因果作用。我们的目的是研究非甾体抗炎药布洛芬 (IBU) 对 MMC 的细胞毒性作用的影响,以及 IBU 预防膀胱功能障碍的潜力。用 MMC 处理恶性 (RT4、T24) 和正常 (UROtsa) 尿路上皮细胞系,然后用布洛芬处理,评估细胞活力和半胱氨酸天冬氨酸蛋白酶-3 活性。雌性 C57BL/6JArc 小鼠 (盐水/对照、MMC、盐水+IBU 和 MMC+IBU) 接受膀胱内治疗 (1 小时),用盐水或 MMC(2mg/ml),IBU(1mg/ml)在饮用水中给予 (7 天)。在治疗前和治疗后 (1、3、7 天) 进行排尿模式分析。使用整个膀胱制剂评估顺应性、收缩反应和尿路上皮介质释放。IBU 选择性地增加了两种恶性细胞系中 MMC 的细胞毒性作用和半胱氨酸天冬氨酸蛋白酶-3 活性,但对 UROtsa 没有影响。MMC 显著增加了 24 小时和 3 天的排尿频率,而给予 IBU 则显著降低了这种作用。MMC 显著增加了自发性收缩的频率,从盐水对照中的 2.3±0.5 次收缩/分钟增加到 4.8±0.16 次收缩/分钟,而 IBU 则保护免受这种变化。有趣的是,尽管 MMC 没有改变神经诱发反应,但在 IBU 两组中均增加了神经诱发反应。IBU 通过减少自发性相位活动和增强神经介导的收缩来改善 MMC 治疗后的排尿功能障碍。膀胱癌患者使用 IBU 可能有助于最小化膀胱内 MMC 治疗相关的泌尿科不良反应。